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PreviewsAre those phospholipids
in your pocket?
The identification of phospholipids ligands for the nuclear receptors SF-1 and LRH-1 raise exciting new questions in the
areas of signaling and metabolism. Do these receptors provide cells with a mechanism to alter genomic activities in
response to phospholipid flux? The tools now exist to address these questions, and more.This year marks the fifteenth anniversary n
of Isseman and Green’s seminal publica- i
ption identifying ligands for what was
then an orphan nuclear receptor— t
cPPARα (Issemann and Green, 1990).
The ensuing period has taught us that v
fsuch publications are the equivalent of
birth announcements—they foretell of a
enew beginnings, exciting twists, and un-
anticipated challenges (Evans, 2004). c
cIdentification of fatty acids and their de-
rivatives as PPARα,γ,δ ligands heralded t
sa new understanding of fatty acid oxida-
tion and lipid storage. Sterol and bile W
aacid ligands for LXRα, β, and FXR con-
tinue to add depth to our perception of i
gcholesterol, bile, and fatty acid homeo-
stasis; interest in drug metabolism was p
crekindled once PXR and CAR were
christened as xenobiotic sensors. And g
tof course, we now have reason to hope
that new drugs are on the horizon for t
vsome of man’s largest killers including
atherosclerosis, diabetes, and obesity. m
fRecent studies from the laboratories
of Ingraham (Krylova et al., 2005), Xu (Li o
det al., 2005), Redinbo (Ortlund et al.,
2005), and their colleagues have made g
Wan equally promising announcement.
These groups have demonstrated that t
tthe mammalian nuclear receptors (NRs)
SF-1 and LRH-1 interact with phosphati- g
idylcholine (PC), phosphatidylethanolam-
ine (PE), phosphatidylglycerol (PG), and n
aperhaps even phosphatidylinositol-phos-
phates (PIPs). Crystallographic analysis a
revealed an unexpected electron density
within the ligand binding pockets of hu- p
gman and mouse SF-1 and human LRH-1.
Further structural analysis and mass t
sspectrometry convincingly demonstrate
that these receptors bind PG and/or PE c
iligands when they are expressed in bac-
teria. c
cSo SF-1 and LRH-1 can bind to phos-
pholipids, but are these ligands func- a
ational? The answer is a resounding yes.
Li et al. (2005) demonstrate that PC and r
mPE bind SF-1 with high affinity (w100CELL METABOLISM : MARCH 2005 · VOL. 1 · CM) and can recruit coactivator peptides f
cn vitro. Furthermore, introduction of
oint mutations that are expected to in- s
Perfere with ligand binding generate re-
eptors that fail to recruit coactivator in e
ditro or to activate transcription in trans-
ected cells (Li et al., 2005; Ortlund et f
tl., 2005). It should be noted that that
ndogenous PG, PE, PC, and PIPs each a
uonsist of a heterogeneous array of
ompounds whose two fatty acyl moie- f
Lies can vary in length (C14–C22) and
aturation (zero to six double bonds; b
rood and Harlow, 1969; Figure 1). Li et
l. (2005) demonstrate that phospholip- p
tds with C12–16 saturated fatty acyl
roups recruit coactivator, while a com- m
pound with C18:2 moieties displaces
oactivator. Structural arguments sug- h
nest that the additional two carbons on
he C18 chain produce a steric clash b
hat could reorient the helix 12/AF2 acti-
ation domain into an inactive confor- c
nation. Thus, phospholipids are not only
unctional SF-1 ligands, but the direction d
df their activity may vary dramatically
epending on the precise fatty acyl a
broups in their sn-1 and sn-2 positions.
hile most endogenous nuclear recep- “
aor ligands are pure agonists, it appears
hat changes in the fatty acyl pool may r
ienerate signals that either activate or
nhibit SF-1/LRH-1. This provides a c
lovel mechanism to toggle physiologic
ctivity in response to rather subtle met- b
dbolic changes.
In addition to the fatty acyl tail, phos- p
iholipids are defined by their polar head
roups. The three-dimensional struc- p
tures reported by both groups demon-
trate that the fatty-acyl groups and the d
wentral phosphate moiety are both bur-
ed within the ligand binding pocket. In m
ontrast, the polar head groups (e.g.,
holine, ethanolamine, glycerol, inositol) t
dre exposed on the surface and do not
ppear to make direct contacts with the p
(eceptor. This raises the possibility that
any classes of phospholipids may tOPYRIGHT © 2005 ELSEVIER INC.unction as ligands, a hypothesis that is
onsistent with Li et al.’s (2005) demon-
tration of similar binding affinities for
E and PC. On the other hand, Krylova
t al. (2005) suggest that PI3-kinase-
erived PIPs bind with much higher af-
inity than PC and PE. At first glance,
his discrepancy might be explained
way on technical grounds: each group
sed phospholipids with slightly dif-
erent fatty acyl side chains. Moreover,
i et al. (2005) simply did not study PIP
inding. Perhaps they also would have
eported higher affinity for these phos-
holipids had they included these in
heir assays? Nonetheless, the fact re-
ains that the crystal structure does not
redict increased affinity for inositide
ead groups, and the reported data do
ot fully exclude the possibility that PIP
inding was nonspecific.
As the orphan field matures, it has be-
ome increasingly clear that commu-
iqués of new ligands are sure to fire up
ebates as to the identity of the true en-
ogenous ligand. While most would
gree that a ligand is a compound that
inds to and modulates an NR, the true
endogenous ligand” is ideally defined
s the molecule that is bound while the
eceptor is active in vivo. This definition
s stringent as it excludes naturally oc-
urring compounds that can function as
igands under experimental conditions
ut whose in vivo concentration, tissue
istribution, or intracellular localization
reclude their interaction with receptor
n target cells. Technical limitations have
revented the widespread implementa-
ion of this definition, but if we apply this
raconian definition to the SF-1/LRH-1,
e quickly realize that the final chapter
ay not yet be written.
Could other molecules represent the
rue endogenous ligand? Perhaps other
iacyl-lipids like phosphatidylserine (PS),
hosphatidic acid (PA), or diacylglycerol
DAG) may fit the bill? The crystal struc-
ures suggest that DAG, a bona fide sig-153
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fFigure 1. Phospholipid ligands for SF-1 and LRH-1
nCompounds proposed to bind to SF-1 and human LRH-1 are denoted with a check mark; −, no binding; ?,
not tested. m
b
bnaling molecule in its own right, is un- P
likely to bind as it lacks the central a
phosphate moiety that is critical for re- c
ceptor interaction. However, PS and PA m
remain potential candidates. In fact, Kry- l
lova et al. (2005) show that inhibition of f
PA production with high concentrations e
of butanol also inhibits receptor activity c
in cells. While future experiments are re- (
quired to demonstrate that exogenous u154A reverses the butanol effect (Fang et s
l., 2001), the current data are at least o
onsistent with the notion that PA (or a k
etabolite) may be a true endogenous t
igand. It will also be important to per- m
orm similar experiments to assess the I
ffect of depleting other phospholipids w
lasses such as PI3 kinase products l
e.g., with chemical inhibitors, RNAi, or s
psing the PTEN phosphatase).The current phospholipid story also
as the potential to reshape our concep-
ual view of a ligand. Consider the case
f a tight/covalently bound ligand, or a
igand whose intracellular concentration
ar exceeds its affinity for the receptor.
uch molecules may provide little regu-
atory function as they would occupy the
eceptor regardless of the physiological
tate of the cell. PC and PE are the two
ost abundant mammalian phospholip-
ds and the main building blocks of
embrane bilayers. Both compounds
re also found in the nuclear matrix
here PC has been estimated to occupy
0% of the total volume (Hunt et al.,
001)! Given the w100 nM affinity of
F-1 for PC, one must consider the pos-
ibility that there is sufficient PC in the
ucleus to drive receptor occupancy un-
er most physiological conditions. If this
s the case, then phospholipids may not
e regulating activity in the dynamic
ense but rather serving as a cofactor
hat stabilizes a “permanently” active
tructure.
There are other tantalizing hints that
upport this structural cofactor hypothe-
is. Many NRs utilize a conserved intra-
olecular interaction that pins helices
0–11 to a loop between helices 6 and
(Shan et al., 2004). Krylova et al. (2005)
uggest that apo SF-1 is incapable of
orming this pin on its own; rather, it
enerates an equivalent structure by co-
pting the ligand’s central phosphate
oiety to form the pin. Interestingly,
ouse LRH-1 does not bind ligand, but
t maintains the integrity of the pin via
mino acid differences that facilitate di-
ect intrareceptor contacts. It seems that
he pin is conserved through evolution;
he ligand is dispensable provided the
in-like structure is maintained. This
upports the possibility that the phos-
holipid ligand is not serving a dynamic
unction. Certainly there can be little dy-
amic regulation in the binding-deficient
ouse receptor. Perhaps the same may
e true in humans if PC is “always”
ound within the LRH-1/SF-1 pocket.
SF-1 and LRH-1 are key regulators of
teroidogenesis and cholesterol metab-
lism. Although phospholipids are not
nown to regulate these events at the
ranscriptional level, the current data
ay force us to rethink this possibility.
ndeed, there are several situations
here one might want to regulate cho-
esterol metabolism via phospholipid
ignals. Such regulatory networks might
rovide a means to fine tune phospho-CELL METABOLISM : MARCH 2005
P R E V I E W SSlipid:cholesterol ratios in membranes or
bile. The data linking phospholipids to E
SF-1 and LRH-1 has already generated
F
new insights and many interesting ques- g
tions. Yes, those are phospholipids in 1
our pockets and we sure are excited! H
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